Autolus Therapeutics plc Research and Development Expense
Autolus Therapeutics plc (AUTL) reported Research and Development Expense of $27.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Autolus Therapeutics plc research and development expense for the quarter ending 2026-06-30 was $27.90M, a 1.71% increase year-over-year.
- Autolus Therapeutics plc research and development expense for the quarter ending 2026-03-31 was $21.21M, a 20.66% decline year-over-year.
- Autolus Therapeutics plc research and development expense for the quarter ending 2025-12-31 was $35.63M, a 15.58% increase year-over-year.
- Autolus Therapeutics plc research and development expense for the quarter ending 2025-09-30 was $27.89M, a 30.83% decline year-over-year.
- Autolus Therapeutics plc research and development expense for fiscal 2025 was $117.69M, a 14.99% decline from fiscal 2024.
- Autolus Therapeutics plc research and development expense for fiscal 2024 was $138.44M, a 6.10% increase from fiscal 2023.
- Autolus Therapeutics plc research and development expense for fiscal 2023 was $130.48M, a 11.19% increase from fiscal 2022.
- Autolus Therapeutics plc research and development expense for fiscal 2022 was $117.35M, a 5.88% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.90M 10-Q · filed 2026-08-11 | $49.11M 10-Q · filed 2026-08-11 | $84.74M derived: sum of 3 quarters · filed 2026-08-11 | $112.63M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $21.21M 10-Q · filed 2026-05-14 | $56.84M derived: sum of 2 quarters · filed 2026-05-14 | $84.73M derived: sum of 3 quarters · filed 2026-05-14 | $112.17M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $35.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $63.52M derived: sum of 2 quarters · filed 2026-03-27 | $90.95M derived: sum of 3 quarters · filed 2026-08-11 | $117.69M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $27.89M 10-Q · filed 2025-11-12 | $55.32M derived: sum of 2 quarters · filed 2026-08-11 | $82.06M 10-Q · filed 2025-11-12 | $112.89M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $27.43M 10-Q · filed 2026-08-11 | $54.16M 10-Q · filed 2026-08-11 | $84.99M derived: sum of 3 quarters · filed 2026-08-11 | $125.32M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $26.73M 10-Q · filed 2026-05-14 | $57.56M derived: sum of 2 quarters · filed 2026-05-14 | $97.89M derived: sum of 3 quarters · filed 2026-05-14 | $134.50M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $30.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $71.15M derived: sum of 2 quarters · filed 2026-03-27 | $107.77M derived: sum of 3 quarters · filed 2026-03-27 | $138.44M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $40.32M 10-Q · filed 2025-11-12 | $76.94M derived: sum of 2 quarters · filed 2025-11-12 | $107.61M 10-Q · filed 2025-11-12 | $145.15M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $36.61M 10-Q · filed 2025-08-12 | $67.28M 10-Q · filed 2025-08-12 | $104.83M derived: sum of 3 quarters · filed 2025-08-12 | $137.14M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $30.67M 10-Q · filed 2025-05-08 | $68.21M derived: sum of 2 quarters · filed 2025-05-08 | $100.53M derived: sum of 3 quarters · filed 2025-05-08 | $133.76M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $37.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $69.86M derived: sum of 2 quarters · filed 2025-03-20 | $103.09M derived: sum of 3 quarters · filed 2025-03-20 | $130.48M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $32.32M 10-Q · filed 2024-11-12 | $37.24M 6-K · filed 2023-11-02 | $65.55M derived: sum of 2 quarters · filed 2024-11-12 | $92.94M 10-Q · filed 2024-11-12 | $105.32M 6-K · filed 2023-11-02 | $100.49M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $33.23M 10-Q · filed 2024-08-08 | $60.62M 10-Q · filed 2024-08-08 | $68.17M derived: sum of 3 quarters · filed 2024-08-08 | $99.65M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $27.39M 10-Q · filed 2024-05-17 | $34.94M derived: sum of 2 quarters · filed 2024-05-17 | $66.42M derived: sum of 3 quarters · filed 2024-05-17 | $97.22M derived: sum of 4 quarters · filed 2024-05-17 | |||
| 2022-12-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $39.03M derived: sum of 2 quarters · filed 2024-03-21 | $69.83M derived: sum of 3 quarters · filed 2024-03-21 | $117.35M 10-K · filed 2024-03-21 | $141.99M 20-F · filed 2023-03-07 | ||
| 2022-09-30 | $31.48M 10-K · filed 2024-03-21 | $37.63M 6-K · filed 2023-11-02 | $62.28M derived: sum of 2 quarters · filed 2024-03-21 | $109.81M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $30.79M 10-K · filed 2024-03-21 | $59.16M derived: sum of 2 quarters · filed 2024-03-21 | |||||
| 2022-03-31 | $28.36M 10-K · filed 2024-03-21 | ||||||
| 2021-12-31 | $110.84M 10-K · filed 2024-03-21 | $134.79M 20-F · filed 2022-03-10 | |||||
| 2021-03-31 | $30.73M 6-K · filed 2021-05-06 | $69.46M derived: sum of 2 quarters · filed 2023-03-07 | $103.00M derived: sum of 3 quarters · filed 2023-03-07 | $134.33M derived: sum of 4 quarters · filed 2023-03-07 | |||
| 2020-12-31 | $38.73M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $72.27M derived: sum of 2 quarters · filed 2023-03-07 | $103.60M derived: sum of 3 quarters · filed 2023-03-07 | $134.89M 20-F · filed 2023-03-07 | |||
| 2020-09-30 | $33.55M 6-K · filed 2020-11-05 | $64.87M derived: sum of 2 quarters · filed 2020-11-05 | $96.16M 6-K · filed 2020-11-05 | $125.53M derived: sum of 4 quarters · filed 2022-03-10 | |||
| 2020-06-30 | $31.33M 6-K · filed 2020-08-06 | $62.62M 6-K · filed 2020-08-06 | $91.98M derived: sum of 3 quarters · filed 2022-03-10 | $119.29M derived: sum of 4 quarters · filed 2022-03-10 | |||
| 2020-03-31 | $31.29M 6-K · filed 2021-05-06 | $60.66M derived: sum of 2 quarters · filed 2022-03-10 | $87.97M derived: sum of 3 quarters · filed 2022-03-10 | $114.14M derived: sum of 4 quarters · filed 2022-03-10 | |||
| 2019-12-31 | $29.37M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | $56.68M derived: sum of 2 quarters · filed 2022-03-10 | $82.85M derived: sum of 3 quarters · filed 2022-03-10 | $105.42M 20-F · filed 2022-03-10 | |||
| 2019-09-30 | $27.31M 6-K · filed 2020-11-05 | $53.48M derived: sum of 2 quarters · filed 2020-11-05 | $76.05M 6-K · filed 2020-11-05 | $93.76M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | $26.17M 6-K · filed 2020-08-06 | $48.74M 6-K · filed 2020-08-06 | $66.45M derived: sum of 3 quarters · filed 2021-03-04 | $76.55M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | $22.57M 6-K · filed 2020-05-07 | $40.28M derived: sum of 2 quarters · filed 2021-03-04 | $50.37M derived: sum of 3 quarters · filed 2021-03-04 | $59.24M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | $17.71M 20-F · filed 2021-03-04 | $27.81M derived: sum of 2 quarters · filed 2021-03-04 | $36.67M derived: sum of 3 quarters · filed 2021-03-04 | ||||
| 2018-09-30 | $10.10M 6-K · filed 2019-11-07 | $18.96M derived: sum of 2 quarters · filed 2019-11-07 | $36.15M 20-F · filed 2021-03-04 | $30.59M 6-K · filed 2019-11-07 | $36.15M 20-F · filed 2020-03-03 | ||
| 2018-06-30 | $8.86M 6-K · filed 2019-08-08 | $20.49M 6-K · filed 2019-08-08 | |||||
| 2017-12-31 | $5.56M 20-F · filed 2019-02-25 | ||||||
| 2017-09-30 | $16.01M 20-F · filed 2020-03-03 | ||||||
| 2016-09-30 | $10.44M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |